JP2019530706A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019530706A5 JP2019530706A5 JP2019518975A JP2019518975A JP2019530706A5 JP 2019530706 A5 JP2019530706 A5 JP 2019530706A5 JP 2019518975 A JP2019518975 A JP 2019518975A JP 2019518975 A JP2019518975 A JP 2019518975A JP 2019530706 A5 JP2019530706 A5 JP 2019530706A5
- Authority
- JP
- Japan
- Prior art keywords
- eribulin
- pharmaceutically acceptable
- acceptable salt
- pembrolizumab
- urothelial cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 claims 15
- UFNVPOGXISZXJD-JBQZKEIOSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-JBQZKEIOSA-N 0.000 claims 13
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 11
- 229960003649 eribulin Drugs 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 229960002621 pembrolizumab Drugs 0.000 claims 9
- 229940079593 drug Drugs 0.000 claims 8
- 230000002055 immunohistochemical effect Effects 0.000 claims 4
- 239000007788 liquid Substances 0.000 claims 4
- 230000001394 metastastic effect Effects 0.000 claims 4
- 206010061289 metastatic neoplasm Diseases 0.000 claims 4
- 201000009030 Carcinoma Diseases 0.000 claims 3
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 229960000439 eribulin mesylate Drugs 0.000 claims 3
- 230000002485 urinary effect Effects 0.000 claims 3
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 229940124060 PD-1 antagonist Drugs 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 2
- 229930006000 Sucrose Natural products 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 229940068968 polysorbate 80 Drugs 0.000 claims 2
- 239000005720 sucrose Substances 0.000 claims 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662408328P | 2016-10-14 | 2016-10-14 | |
| US62/408,328 | 2016-10-14 | ||
| PCT/US2017/056552 WO2018071792A1 (en) | 2016-10-14 | 2017-10-13 | Combination of a pd-1 antagonist and eribulin for treating urothelial cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019530706A JP2019530706A (ja) | 2019-10-24 |
| JP2019530706A5 true JP2019530706A5 (enExample) | 2020-11-12 |
Family
ID=60388115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019518975A Withdrawn JP2019530706A (ja) | 2016-10-14 | 2017-10-13 | 尿路上皮がんを治療するための、ｐｄ−１アンタゴニスト及びエリブリンの組合せ |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20190263927A1 (enExample) |
| EP (1) | EP3525818A1 (enExample) |
| JP (1) | JP2019530706A (enExample) |
| KR (1) | KR20190082782A (enExample) |
| CN (1) | CN110072552A (enExample) |
| AU (1) | AU2017342462A1 (enExample) |
| BR (1) | BR112019007145A2 (enExample) |
| CA (1) | CA3040465A1 (enExample) |
| IL (1) | IL265917A (enExample) |
| MX (1) | MX2019003994A (enExample) |
| SG (1) | SG11201902974PA (enExample) |
| WO (1) | WO2018071792A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5191537B2 (ja) | 2007-06-18 | 2013-05-08 | エム・エス・ディー・オス・ベー・フェー | ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体 |
| SI2415470T1 (sl) | 2009-03-30 | 2016-12-30 | Eisai R&D Management Co., Ltd. | Liposomski sestavek |
| EP3449921B1 (en) | 2016-04-28 | 2023-05-31 | Eisai R&D Management Co., Ltd. | Eribulin for inhibiting tumor growth |
| WO2021005546A1 (en) * | 2019-07-09 | 2021-01-14 | Cadila Healthcare Limited | Antibodies to human programmed death receptor pd-1 |
| US11083705B2 (en) * | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| US20230355757A1 (en) * | 2019-12-20 | 2023-11-09 | Formycon Ag | Formulations of anti-pd1 antibodies |
| CN115925954A (zh) * | 2022-12-28 | 2023-04-07 | 广州誉衡生物科技有限公司 | 抗-pd-1抗体及其在制备治疗尿路上皮癌患者的药物中的用途 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL139960A0 (en) | 1998-06-17 | 2002-02-10 | Eisai Co Ltd | Macrocylic analogs and methods of their use and preparation |
| CA2352572C (en) | 1998-12-01 | 2010-04-20 | Abbvie Biotherapeutics Inc. | Humanized antibodies to gamma-interferon |
| EP2206517B1 (en) | 2002-07-03 | 2023-08-02 | Ono Pharmaceutical Co., Ltd. | Immunopotentiating compositions comprising anti-PD-L1 antibodies |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| CN101899026B (zh) | 2004-06-03 | 2016-08-03 | 卫材R&D管理有限公司 | 用于制备软海绵素b的类似物的中间体 |
| US9707302B2 (en) * | 2013-07-23 | 2017-07-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| ES2720160T3 (es) | 2005-05-09 | 2019-07-18 | Ono Pharmaceutical Co | Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas |
| EA019344B1 (ru) | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| JP5191537B2 (ja) | 2007-06-18 | 2013-05-08 | エム・エス・ディー・オス・ベー・フェー | ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体 |
| BRPI0817909B1 (pt) | 2007-10-03 | 2022-06-21 | Eisai R&D Management Co., Ltd | Métodos de obtenção e de preparação de uma composição diastereomericamente pura, compostos, e método para produzir os referidos compostos |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| EP2328920A2 (en) | 2008-08-25 | 2011-06-08 | Amplimmune, Inc. | Targeted costimulatory polypeptides and methods of use to treat cancer |
| BRPI0919377A2 (pt) | 2008-09-26 | 2016-09-27 | Dana Farber Cancer Inst Inc | anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento |
| HUE065752T2 (hu) | 2008-12-09 | 2024-06-28 | Hoffmann La Roche | Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| BR112012018232B8 (pt) | 2010-01-26 | 2023-01-10 | Eisai R&D Man Co Ltd | Compostos derivados de furo [3,2-b] pirano úteis na síntese de análogos de halicondrina b e métodos de sintetização de er-80402 e de eribulina |
| CA2830806C (en) | 2011-03-31 | 2020-05-12 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments |
| EA026924B1 (ru) | 2011-08-01 | 2017-05-31 | Дженентек, Инк. | Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| MA40921A (fr) * | 2014-11-05 | 2017-09-12 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation |
| IL286282B2 (en) * | 2015-02-12 | 2023-10-01 | Beyondspring Pharmaceuticals Inc | Use of palinabolin in combination with immune checkpoint inhibitors |
| JP6951248B2 (ja) * | 2015-03-04 | 2021-10-20 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | がんを治療するための、ｐｄ−１アンタゴニスト及びエリブリンの組合せ |
-
2017
- 2017-10-13 JP JP2019518975A patent/JP2019530706A/ja not_active Withdrawn
- 2017-10-13 MX MX2019003994A patent/MX2019003994A/es unknown
- 2017-10-13 KR KR1020197013370A patent/KR20190082782A/ko not_active Withdrawn
- 2017-10-13 EP EP17800964.3A patent/EP3525818A1/en not_active Withdrawn
- 2017-10-13 BR BR112019007145A patent/BR112019007145A2/pt not_active IP Right Cessation
- 2017-10-13 CN CN201780077525.7A patent/CN110072552A/zh active Pending
- 2017-10-13 CA CA3040465A patent/CA3040465A1/en not_active Abandoned
- 2017-10-13 US US16/341,579 patent/US20190263927A1/en not_active Abandoned
- 2017-10-13 SG SG11201902974PA patent/SG11201902974PA/en unknown
- 2017-10-13 WO PCT/US2017/056552 patent/WO2018071792A1/en not_active Ceased
- 2017-10-13 AU AU2017342462A patent/AU2017342462A1/en not_active Abandoned
-
2019
- 2019-04-08 IL IL265917A patent/IL265917A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019530706A5 (enExample) | ||
| JP2018508516A5 (enExample) | ||
| RU2017132877A (ru) | Комбинация антагониста pd-1 и эрибулина для лечения рака | |
| JP2018512391A5 (enExample) | ||
| JP2016530280A5 (enExample) | ||
| WO2015097621A3 (en) | Pharmaceutical combinations | |
| JP2017506227A5 (enExample) | ||
| BR112015029512A8 (pt) | derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas | |
| FI3519049T3 (fi) | Turvallinen ja tehokas menetelmä psoriaasin hoitamiseen il23- spesifisellä vasta-aineella | |
| AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
| JP2019532047A5 (enExample) | ||
| JP2018530578A5 (enExample) | ||
| JP2015517523A5 (enExample) | ||
| JP2018521064A5 (enExample) | ||
| JP2018039810A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| JP2021505669A5 (enExample) | ||
| Sturn et al. | Low-dose naltrexone: a new therapy option for complex regional pain syndrome type I patients | |
| JP2018506533A5 (enExample) | ||
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. | |
| FI3359572T3 (fi) | Menetelmä multippeliskleroosin hoitamiseksi | |
| RU2015139515A (ru) | Комбинированное лечение | |
| JP2015510945A5 (enExample) | ||
| IL275091B2 (en) | Methods for treating gaucher disease | |
| JP2020512408A5 (enExample) |